Respiratory Disease News and Research

RSS

Roche ships additional quantities of Tamiflu oral suspension

Roche announced today that it has begun shipping additional quantities of Tamiflu® (oseltamivir phosphate) oral suspension (liquid).

3 Dec 2009

MicroDose Therapeutx acquires a portfolio of compounds from Epix Pharmaceuticals

MicroDose Therapeutx Inc. today announced that it has acquired a portfolio of compounds for the potential treatment of chronic constipation, irritable bowel syndrome with constipation (IBS-C) and other diseases, from Epix Pharmaceuticals, Inc. (EPIX) (Lexington, MA).

2 Dec 2009

Climate change to have a profound impact on global public health

An emerging body of evidence suggests that the changing global climate is already affecting infectious disease transmission patterns. As noted today in a symposium at the 58th annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), such changes are expected to have a profound impact on global public health.

21 Nov 2009

Scientists explore various imaging techniques to gain new insight into lung disease

Chronic obstructive pulmonary disease (COPD), a respiratory disease commonly known as chronic bronchitis or emphysema, is the fourth leading cause of death worldwide. 600 million people live with COPD and while researchers have yet to find any real treatment or cure, Grace Parraga of Robarts Research Institute at The University of Western Ontario in London, Canada, is using various imaging techniques to gain new insight into the disease.

21 Nov 2009

Canadian comedian helps raise awareness about COPD

COPD is no joke to Canadian comedian Mary Walsh. "It's shocking that so few Canadians know about COPD considering it's the fourth leading cause of death in this country," says Mary Walsh, spokesperson for The Canadian Lung Association.

18 Nov 2009

MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus

MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA). The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637.

10 Nov 2009

NIOSH funds the DUSTI project

In the construction industry, respiratory disease, often leading to disability or an increased risk of cancer, is a major public health concern. Studies led by Deborah Young-Corbett, a faculty member in Virginia Tech's School of Construction, have shown that specific types of sanding tools are highly effective in reducing the dust that causes these health hazards, yet the industry's usage of the available technology remains very low.

10 Nov 2009

Exposure to higher levels of air pollution increases infants' risk for bronchiolitis

Infants who are exposed to higher levels of air pollution are at increased risk for bronchiolitis, according to a new study.

6 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Third quarter 2009 financial results announced by Aradigm

Aradigm Corporation (OTCBB:ARDM) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2009 and recent highlights.

5 Nov 2009

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has advanced to the RNAi therapeutic collaboration stage of its landmark alliance with Roche formed in 2007.

4 Nov 2009

Vaccinating mothers against influeza during pregnancy prevents hospitalization in their infants

Infants born to women who received influenza vaccine during pregnancy were hospitalized at a lower rate than infants born to unvaccinated mothers, according to preliminary results of an ongoing study by researchers at Yale School of Medicine. The team presented the study October 29 at the 47th annual meeting of the Infectious Diseases Society of America in Philadelphia.

3 Nov 2009

Replenish+ delays the progression of AIDS in HIV-infected patients not receiving ART

Data presented today from a 310 patient, 52 week, double-blind, controlled clinical trial demonstrates that a micronutrient supplement, Replenish+™ delays the progression of AIDS in HIV-infected patients not receiving antiretroviral treatment (ART).

31 Oct 2009

Avicenna's work on respiratory diseases highlighted in SAGE journal

For pulmonary ailments, certain mediaeval physicians had a useful medical textbook on hand offering detailed information remarkably similar to those a modern doctor might use today. One of the fathers of medicine, the great Persian scholar Avicenna left a wealth of information in his many works. Iranian academics dust off one of these in an article published today in the SAGE journal Therapeutic Advances in Respiratory Disease, sharing in English details of Avicenna's work that still fascinate both physicians and historians of medicine alike.

30 Oct 2009

NIH awards contract to LRRI for anthrax research

Lovelace Respiratory Research Institute (LRRI) was recently awarded a contract to continue research due to the potential for bioterrorist attacks involving Bacillus anthracis, the causative agent of anthrax, by the National Institutes of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health (NIH).

29 Oct 2009

Lovelace Respiratory Research Institute and Brigham and Women's Hospital collaborate on respiratory diseases research

Lovelace Respiratory Research Institute (LRRI) recently announced the formation of a research agreement between the Division of Pulmonary and Critical Care Medicine of the Department of Medicine at Brigham and Women's Hospital (BWH), teaching hospital of Harvard Medical School in Boston.

28 Oct 2009

Micronics inks license agreement with Biosearch Technologies

Micronics, Inc., a leading developer of point-of-care molecular diagnostic products, announced today that it has entered into a license agreement with Biosearch Technologies, Inc. (Biosearch) for the right to make, have made, use and sell Micronics’ products that incorporate Biosearch’s proprietary fluorophores and quencher dyes for nucleic acid assays. Under the terms of the worldwide license, Biosearch has granted Micronics a royalty-free use of certain of its chemistries for inclusion in Micronics’ infectious disease tests for sale in underdeveloped countries.

28 Oct 2009

Theravance earns milestone payment for bactericidal, injectable lipoglycopeptide antibiotic

Theravance, Inc. announced today that it has earned a milestone payment of $20 million for the U.S. Food and Drug Administration (FDA) approval of VIBATIV (telavancin) and supplying its collaboration partner, Astellas Pharma US, Inc. (Astellas), with the launch inventory for the first commercial sale in the United States.

23 Oct 2009

American Thoracic Society releases new clinical guidelines for pulmonary exacerbation of cystic fibrosis

The American Thoracic Society has released new clinical guidelines for the treatment of exacerbations in cystic fibrosis based on a review of the literature on current clinical practices.